|
RCHY1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
1.99089999997071E-06 |
| Normal-vs-Stage3 |
8.92619311798626E-14 |
| Normal-vs-Stage4 |
3.33066907387547E-16 |
| Stage1-vs-Stage2 |
1.559190E-01 |
| Stage1-vs-Stage3 |
1.658770E-01 |
| Stage1-vs-Stage4 |
1.778520E-04 |
| Stage2-vs-Stage3 |
3.976200E-02 |
| Stage2-vs-Stage4 |
3.374100E-04 |
| Stage3-vs-Stage4 |
3.080200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.70440000002436E-06 |
| Normal-vs-Asian |
2.04229999578587E-09 |
| Caucasian-vs-AfricanAmerican |
5.958200E-01 |
| Caucasian-vs-Asian |
4.611000E-01 |
| AfricanAmerican-vs-Asian |
9.889200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
1.012650E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62903024403249E-12 |
| Normal-vs-Age(41-60Yrs) |
2.50466314355435E-13 |
| Normal-vs-Age(61-80Yrs) |
1.62636570877339E-12 |
| Normal-vs-Age(81-100Yrs) |
1.020010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.465600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.572200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.448000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.363400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.348600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.172000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.971000E-04 |
| Classical-VS-Follicular |
6.443900E-02 |
| Classical-VS-Other |
4.815200E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
3.60590000000327E-05 |
| Tall-VS-Other |
3.725200E-01 |
| Tall-VS-Normal |
5.99520433297585E-15 |
| Follicular-VS-Other |
2.540800E-01 |
| Follicular-VS-Normal |
3.66900000048354E-07 |
| Other-VS-Normal |
4.409800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.79456491070596E-14 |
| Normal-vs-N1 |
3.67483821150927E-14 |
| N0-vs-N1 |
9.260000E-03 |
|
|
